- Residency - Harvard/Brigham and Women's Hospital/Massachusetts General Hospital (2008-2012), Radiation Oncology
- Internship - Harvard/Brigham and Women's Hospital (2007-2008), Internal Medicine
- Medical School - Stanford University School of Medicine (1999-2007)
- Graduate School - Stanford University, Medical Scientist Training Program
- Other Post Graduate Training - Stanford University
Ken Westover, M.D., Ph.D.
- Radiation Oncology
- Radiation Therapy for Esophageal Cancer
- Chest Cancers
Ken Westover, M.D., Ph.D., started his research career as a summer undergraduate research fellow in the labs of Nobel Prize laureates Michael Brown, M.D., and Joseph Goldstein, M.D., at UT Southwestern. It was there that he learned the basics of biochemistry and became convinced that he wanted to become a physician-scientist.
After graduating with honors from Brigham Young University, with a B.S. in biochemistry, Dr. Westover entered the Stanford University Medical Scientist Training Program where he worked in the lab of Roger Kornberg, Ph.D., on the structural biology and biochemistry of gene transcription. Dr. Westover’s work was subsequently cited in the 2006 Nobel Prize for Chemistry awarded to Dr. Kornberg.
Radiation oncology was a natural fit for Dr. Westover given his laboratory experience, which had natural connections to cancer biology and included elements of imaging research, radiation science, and computer science. Most importantly, Dr. Westover found he was passionate about the practice of oncology.
Dr. Westover completed his residency in radiation oncology at the Harvard Radiation Oncology Program, where he simultaneously worked in the lab of Nathanael Gray, Ph.D., in the Dana Farber Cancer Institute, learning principles of structure-based drug design and chemical biology. He also completed Harvard’s Intensive Translational Research Program.
Now at UT Southwestern, Dr. Westover focuses his clinical efforts on
lung cancer and his research efforts on improving cancer therapies. In
addition to targeted drug design, Dr. Westover hopes to find new ways to
combine radiation therapy and targeted drugs.
Meet Dr. Westover
Ken Westover, M.D., Ph.D., wears many hats. He is a member of the lung cancer team, Director of Information Technology and Innovation for the Department of Radiation Oncology, and Director of the Westover Research Laboratory, located in the Department of Biochemistry, which is dedicated to cancer biology and the development of new drugs.
"I look at cancer from its molecular basis to the physics of radiation treatment.”
After completion of the Stanford University Medical Scientist Training Program (1999-2007) and residency training in Harvard Radiation Oncology Program (2007-2012) where he distinguished himself as a fellow in radiation oncology and a scientist specializing in drug development for cancer, Dr. Westover was recruited to UT Southwestern.
Westover’s work has been published in numerous clinical and high-profile basic science journals. He has also authored several book chapters relating to radiation therapy. His scientific work shed light on the way genes are transcribed and was cited in the 2006 Nobel Prize in Chemistry awarded to his mentor Roger Kornberg, Ph.D.
“I want to relieve the burdens of cancer in any way I can. I am fully committed to serving cancer patients through basic research, clinical innovation, and the highest quality patient care,” says Dr. Westover. “I feel fortunate to work with several highly skilled teams that are making a difference for cancer patients.”
Clinically, Dr. Westover specializes in treating lung cancer and is particularly interested in using stereotactic body radiation therapy (SBRT) – also known as stereotactic ablative radiation therapy (SABR) – to treat cancer patients, an approach that was pioneered by another member of UT Southwestern’s radiation oncology team, Robert Timmerman, M.D. This stronger, “ablative” dose of radiation precisely targets and destroys tumors in just a few treatments.
In the lab, Dr. Westover is focused on developing targeted drugs and
understanding how certain mutant proteins cause cancer. While at Harvard
he was the first to publish clinical results showing that protons can
be used to deliver effective SBRT for early stage lung cancer in
patients with poor pulmonary function.
- American Association for Cancer Research
- American College of Radiology
- American Society for Therapeutic Radiation and Oncology
- CPRIT Scholar 2012-2016
- V Scholar 2014-2016
Radiation in Pocket Neurology
Westover MB, Choi E, Awad K (2010), Philadelphia, PA, Lippincott Williams & Wilkins
Liver in Human Radiation Injury
Shrieve D, Loeffler J, et al (2010), Philadelphia, PA, Lippincott Williams & Wilkins
- Radiation in Pocket Neurology
Safety Analysis From a Prospective Registry Study of Stereotactic Body Radiation Therapy for Aggressive Management of Late-Stage Disease.
Maquilan G, Westover KD, Wardak Z, Timmerman RD, Hannan R, Iyengar P, Schwartz DL, Meyer JJ, Abdulrahman RE, Folkert MR, Laine AM, Desai NB, Albuquerque KV, Choy H, Ahn C, Rahimi AS International journal of radiation oncology, biology, physics 2016 Oct 96 2S E527
A Phase III Randomized Study of Image Guided Conventional (60 Gy/30 fx) Versus Accelerated, Hypofractionated (60 Gy/15 fx) Radiation for Poor Performance Status Stage II and III NSCLC Patients-An Interim Analysis.
Iyengar P, Westover KD, Court LE, Patel MK, Shivnani AT, Saunders MW, Li Y, Chang JY, Gao A, Ahn C, Choy H, Timmerman RD International journal of radiation oncology, biology, physics 2016 Oct 96 2S E451
Shell feature: a new radiomics descriptor for predicting distant failure after radiotherapy in non-small cell lung cancer and cervix cancer.
Hao H, Zhou Z, Li S, Maquilan G, Folkert MR, Iyengar P, Westover KD, Albuquerque K, Liu F, Choy H, Timmerman RD, Yang L, Wang J Physics in medicine and biology 2018 Apr
Multi-objective radiomics model for predicting distant failure in lung SBRT.
Zhou Z, Folkert M, Iyengar P, Westover K, Zhang Y, Choy H, Timmerman R, Jiang S, Wang J Physics in medicine and biology 2017 Jun 62 11 4460-4478
GADD45a sensitizes cervical cancer cells to radiotherapy via increasing cytoplasmic APE1 level.
Li Q, Wei X, Zhou ZW, Wang SN, Jin H, Chen KJ, Luo J, Westover KD, Wang JM, Wang D, Xu CX, Shan JL Cell death & disease 2018 May 9 5 524
KRAS G12C Drug Development: Discrimination between Switch II Pocket Configurations Using Hydrogen/Deuterium-Exchange Mass Spectrometry.
Lu J, Harrison RA, Li L, Zeng M, Gondi S, Scott D, Gray NS, Engen JR, Westover KD Structure (London, England : 1993) 2017 Jul
Automated Text Message Reminders Improve Radiation Therapy Compliance.
Tan J, Christie A, Montalvo SK, Wallace C, Yan Y, Folkerts M, Yingling A, Sher D, Choy H, Jiang S, Westover KD International journal of radiation oncology, biology, physics 2018 Nov
Three-dimensional printer-aided casting of soft, custom silicone boluses (SCSBs) for head and neck radiation therapy.
Chiu T, Tan J, Brenner M, Gu X, Yang M, Westover K, Strom T, Sher D, Jiang S, Zhao B Practical radiation oncology 2017 Nov
A pilot study using kernelled support tensor machine for distant failure prediction in lung SBRT.
Li S, Yang N, Li B, Zhou Z, Hao H, Folkert MR, Iyengar P, Westover K, Choy H, Timmerman R, Jiang S, Wang J Medical image analysis 2018 Sep 50 106-116
Takinib, a Selective TAK1 Inhibitor, Broadens the Therapeutic Efficacy of TNF-a Inhibition for Cancer and Autoimmune Disease.
Totzke J, Gurbani D, Raphemot R, Hughes PF, Bodoor K, Carlson DA, Loiselle DR, Bera AK, Eibschutz LS, Perkins MM, Eubanks AL, Campbell PL, Fox DA, Westover KD, Haystead TAJ, Derbyshire ER Cell chemical biology 2017 Aug 24 8 1029-1039.e7
Accurate real time localization tracking in a clinical environment using Bluetooth Low Energy and deep learning.
Iqbal Z, Luo D, Henry P, Kazemifar S, Rozario T, Yan Y, Westover K, Lu W, Nguyen D, Long T, Wang J, Choy H, Jiang S PloS one 2018 13 10 e0205392
KRAS Switch Mutants D33E and A59G Crystallize in the State 1 Conformation.
Lu J, Bera AK, Gondi S, Westover KD Biochemistry 2017 Dec
KRAS Dimerization Impacts MEK Inhibitor Sensitivity and Oncogenic Activity of Mutant KRAS.
Ambrogio C, Köhler J, Zhou ZW, Wang H, Paranal R, Li J, Capelletti M, Caffarra C, Li S, Lv Q, Gondi S, Hunter JC, Lu J, Chiarle R, Santamaría D, Westover KD, Jänne PA Cell 2018 Jan
Potent and Selective Covalent Quinazoline Inhibitors of KRAS G12C.
Zeng M, Lu J, Li L, Feru F, Quan C, Gero TW, Ficarro SB, Xiong Y, Ambrogio C, Paranal RM, Catalano M, Shao J, Wong KK, Marto JA, Fischer ES, Jänne PA, Scott DA, Westover KD, Gray NS Cell chemical biology 2017 Aug 24 8 1005-1016.e3
Stereotactic Ablative Radiotherapy (SABR) for Non-Small Cell Lung Cancer.
Iyengar P, Westover K, Timmerman RD Seminars in respiratory and critical care medicine 2013 Dec 34 6 845-54
Consolidative Radiotherapy for Limited Metastatic Non-Small-Cell Lung Cancer: A Phase 2 Randomized Clinical Trial.
Iyengar P, Wardak Z, Gerber DE, Tumati V, Ahn C, Hughes RS, Dowell JE, Cheedella N, Nedzi L, Westover KD, Pulipparacharuvil S, Choy H, Timmerman RD JAMA oncology 2017 Sep e173501
Predicting Distant Failure in Lung Stereotactic Body Radiation Therapy Using Multiobjective Radiomics Model.
Zhou Z, Folkert MR, Iyengar P, Zhang Y, Westover KD, Wang J International journal of radiation oncology, biology, physics 2016 Oct 96 2S S193-S194
Rationale for RAS mutation-tailored therapies.
Montalvo SK, Li L, Westover KD Future oncology (London, England) 2016 Oct
Progress on Covalent Inhibition of KRASG12C.
Westover KD, Jänne PA, Gray NS Cancer discovery 2016 Mar 6 3 233-4
Studies of TAK1-centered polypharmacology with novel covalent TAK1 inhibitors.
Tan L, Gurbani D, Weisberg EL, Jones DS, Rao S, Singer WD, Bernard FM, Mowafy S, Jenney A, Du G, Nonami A, Griffin JD, Lauffenburger DA, Westover KD, Sorger PK, Gray NS Bioorganic & medicinal chemistry 2016 Dec
Data publication with the structural biology data grid supports live analysis.
Meyer PA, Socias S, Key J, Ransey E, Tjon EC, Buschiazzo A, Lei M, Botka C, Withrow J, Neau D, Rajashankar K, Anderson KS, Baxter RH, Blacklow SC, Boggon TJ, Bonvin AM, Borek D, Brett TJ, Caflisch A, Chang CI, Chazin WJ, Corbett KD, Cosgrove MS, Crosson S, Dhe-Paganon S, Di Cera E, Drennan CL, Eck MJ, Eichman BF, Fan QR, Ferré-D'Amaré AR, Christopher Fromme J, Garcia KC, Gaudet R, Gong P, Harrison SC, Heldwein EE, Jia Z, Keenan RJ, Kruse AC, Kvansakul M, McLellan JS, Modis Y, Nam Y, Otwinowski Z, Pai EF, Pereira PJ, Petosa C, Raman CS, Rapoport TA, Roll-Mecak A, Rosen MK, Rudenko G, Schlessinger J, Schwartz TU, Shamoo Y, Sondermann H, Tao YJ, Tolia NH, Tsodikov OV, Westover KD, Wu H, Foster I, Fraser JS, Maia FR, Gonen T, Kirchhausen T, Diederichs K, Crosas M, Sliz P Nature communications 2016 7 10882
SABR for aggressive local therapy of metastatic cancer: A new paradigm for metastatic non-small cell lung cancer.
Westover KD, Iyengar P, Sharma AN, Timmerman R Lung cancer (Amsterdam, Netherlands) 2015 May
Biochemical and Structural Analysis of Common Cancer-Associated KRAS Mutations.
Hunter JC, Manandhar A, Carrasco MA, Gurbani D, Gondi S, Westover KD Molecular cancer research : MCR 2015 Jun
Therapeutic Targeting of Oncogenic K-Ras by a Covalent Catalytic Site Inhibitor.
Lim SM, Westover KD, Ficarro SB, Harrison RA, Choi HG, Pacold ME, Carrasco M, Hunter J, Kim ND, Xie T, Sim T, Jänne PA, Meyerson M, Marto JA, Engen JR, Gray NS Angewandte Chemie (International ed. in English) 2013 Nov
Proton SBRT for medically inoperable stage I NSCLC.
Westover KD, Seco J, Adams JA, Lanuti M, Choi NC, Engelsman M, Willers H Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2012 Jun 7 6 1021-5
Radical prostatectomy vs radiation therapy and androgen-suppression therapy in high-risk prostate cancer.
Westover K, Chen MH, Moul J, Robertson C, Polascik T, Dosoretz D, Katin M, Salenius S, D'Amico AV BJU international 2012 Apr
Significance testing as perverse probabilistic reasoning.
Westover MB, Westover KD, Bianchi MT BMC medicine 2011 9 20
Mycotic aneurysm of the left main coronary artery producing acute coronary occlusion and purulent pericarditis.
Westover K, Benedick B International journal of cardiology 2007 Jan 114 3 e81-2
Structural basis of transcription: role of the trigger loop in substrate specificity and catalysis.
Wang D, Bushnell DA, Westover KD, Kaplan CD, Kornberg RD Cell 2006 Dec 127 5 941-54
Structural basis of transcription: nucleotide selection by rotation in the RNA polymerase II active center.
Westover KD, Bushnell DA, Kornberg RD Cell 2004 Nov 119 4 481-9
Structural basis of transcription: separation of RNA from DNA by RNA polymerase II.
Westover KD, Bushnell DA, Kornberg RD Science (New York, N.Y.) 2004 Feb 303 5660 1014-6
Diffusion of nucleoside triphosphates and role of the entry site to the RNA polymerase II active center.
Batada NN, Westover KD, Bushnell DA, Levitt M, Kornberg RD Proceedings of the National Academy of Sciences of the United States of America 2004 Dec 101 50 17361-4
Nonsteroidal anti-inflammatory drugs, acetaminophen, cyclooxygenase 2, and fever.
Simmons DL, Wagner D, Westover K Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2000 Oct 31 Suppl 5 S211-8
Covalent Guanosine Mimetic Inhibitors of G12C KRAS.
Xiong Y, Lu J, Hunter J, Li L, Scott D, Choi HG, Lim SM, Manandhar A, Gondi S, Sim T, Westover KD, Gray NS ACS medicinal chemistry letters 2017 Jan 8 1 61-66
Structural dynamics in Ras and related proteins upon nucleotide switching.
Harrison RA, Lu J, Carrasco M, Hunter J, Manandhar A, Gondi S, Westover KD, Engen JR Journal of molecular biology 2016 Oct
Torin2 Suppresses Ionizing Radiation-Induced DNA Damage Repair.
Udayakumar D, Pandita RK, Horikoshi N, Liu Y, Liu Q, Wong KK, Hunt CR, Gray NS, Minna JD, Pandita TK, Westover KD Radiation research 2016 May 185 5 527-38
Structure-guided development of covalent TAK1 inhibitors.
Tan L, Gurbani D, Weisberg EL, Hunter JC, Li L, Jones DS, Ficarro SB, Mowafy S, Tam CP, Rao S, Du G, Griffin JD, Sorger PK, Marto JA, Westover KD, Gray NS Bioorganic & medicinal chemistry 2016 Dec
A PHGDH inhibitor reveals coordination of serine synthesis and one-carbon unit fate.
Pacold ME, Brimacombe KR, Chan SH, Rohde JM, Lewis CA, Swier LJ, Possemato R, Chen WW, Sullivan LB, Fiske BP, Cho S, Freinkman E, Birsoy K, Abu-Remaileh M, Shaul YD, Liu CM, Zhou M, Koh MJ, Chung H, Davidson SM, Luengo A, Wang AQ, Xu X, Yasgar A, Liu L, Rai G, Westover KD, Vander Heiden MG, Shen M, Gray NS, Boxer MB, Sabatini DM Nature chemical biology 2016 Apr
Development of small molecules targeting the pseudokinase Her3.
Lim SM, Xie T, Westover KD, Ficarro SB, Tae HS, Gurbani D, Sim T, Marto JA, Jänne PA, Crews CM, Gray NS Bioorganic & medicinal chemistry letters 2015 May
Structural dataset for the fast-exchanging KRAS G13D.
Lu J, Hunter J, Manandhar A, Gurbani D, Westover KD Data in brief 2015 Dec 5 572-8
Pharmacological targeting of the pseudokinase Her3.
Xie T, Lim SM, Westover KD, Dodge ME, Ercan D, Ficarro SB, Udayakumar D, Gurbani D, Tae HS, Riddle SM, Sim T, Marto JA, Jänne PA, Crews CM, Gray NS Nature chemical biology 2014 Oct
Neutrophil-lymphocyte and platelet-lymphocyte ratios as prognostic factors following stereotactic radiation therapy for early-stage non-small cell lung cancer.
Cannon NA, Meyer J, Iyengar P, Ahn C, Westover KD, Choy H, Timmerman R Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2014 Oct
Radiation therapy as a backbone of treatment of locally advanced non-small cell lung cancer.
Laine AM, Westover KD, Choy H Seminars in oncology 2014 Feb 41 1 57-68
Characterization of Torin2, an ATP-competitive inhibitor of mTOR, ATM and ATR.
Liu Q, Xu C, Kirubakaran S, Zhang X, Hur W, Liu Y, Kwiatkowski NP, Wang J, Westover KD, Gao P, Ercan D, Niepel M, Thoreen CC, Kang SA, Patricelli MP, Wang Y, Tupper T, Altabef A, Kawamura H, Held KD, Chou DM, Elledge SJ, Janne PA, Wong KK, Sabatini DM, Gray NS Cancer research 2013 Feb
Treatment of non-small cell lung cancer patients with proton beam-based stereotactic body radiotherapy: dosimetric comparison with photon plans highlights importance of range uncertainty.
Seco J, Panahandeh HR, Westover K, Adams J, Willers H International journal of radiation oncology, biology, physics 2012 May 83 1 354-61
Structural basis of eukaryotic gene transcription.
Boeger H, Bushnell DA, Davis R, Griesenbeck J, Lorch Y, Strattan JS, Westover KD, Kornberg RD FEBS letters 2005 Feb 579 4 899-903
Predicting distant failure in early stage NSCLC treated with SBRT using clinical parameters.
Zhou Z, Folkert M, Cannon N, Iyengar P, Westover K, Zhang Y, Choy H, Timmerman R, Yan J, Xie XJ, Jiang S, Wang J Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2016 May
Inhibition of Cell Proliferation in an NRAS Mutant Melanoma Cell Line by Combining Sorafenib and a-Mangostin.
Xia Y, Li Y, Westover KD, Sun J, Chen H, Zhang J, Fisher DE PloS one 2016 11 5 e0155217
In situ selectivity profiling and crystal structure of SML-8-73-1, an active site inhibitor of oncogenic K-Ras G12C
John C. Hunter, Deepak Gurbani, Scott B. Ficarro, Martin A. Carrasco, Sang Min Lim, Hwan Geun Choi, Ting Xie, Jarrod A. Marto, Zhe Chen, Nathanael S. Gray, and Kenneth D. Westover Proceedings of the National Academy of Sciences, USA 2014 Early Edition
Kinome-wide selectivity profiling of ATP-competitive mammalian target of rapamycin (mTOR) inhibitors and characterization of their binding kinetics.
Liu Q, Kirubakaran S, Hur W, Niepel M, Westover K, Thoreen CC, Wang J, Ni J, Patricelli MP, Vogel K, Riddle S, Waller DL, Traynor R, Sanda T, Zhao Z, Kang SA, Zhao J, Look AT, Sorger PK, Sabatini DM, Gray NS The Journal of biological chemistry 2012 Mar 287 13 9742-52
Should a sentinel node biopsy be performed in patients with high-risk breast cancer?
Westover KD, Westover MB, Winer EP, Richardson AL, Iglehart JD, Punglia RS International journal of breast cancer 2011 2011 973245
Structural basis of transcription: backtracked RNA polymerase II at 3.4 angstrom resolution.
Wang D, Bushnell DA, Huang X, Westover KD, Levitt M, Kornberg RD Science (New York, N.Y.) 2009 May 324 5931 1203-6
Determination of expression of cyclooxygenase-1 and -2 isozymes in canine tissues and their differential sensitivity to nonsteroidal anti-inflammatory drugs.
Wilson JE, Chandrasekharan NV, Westover KD, Eager KB, Simmons DL American journal of veterinary research 2004 Jun 65 6 810-8
Mechanism of Rab geranylgeranylation: formation of the catalytic ternary complex.
Anant JS, Desnoyers L, Machius M, Demeler B, Hansen JC, Westover KD, Deisenhofer J, Seabra MC Biochemistry 1998 Sep 37 36 12559-68
Structural and Biochemical Analyses Reveal the Mechanism of Glutathione S-Transferase Pi 1 Inhibition by the Anti-cancer Compound Piperlongumine.
Harshbarger W, Gondi S, Ficarro SB, Hunter J, Udayakumar D, Gurbani D, Singer W, Liu Y, Li L, Marto JA, Westover KD The Journal of biological chemistry 2016 Nov
Direct Targeting of ß-Catenin by a Small Molecule Stimulates Proteasomal Degradation and Suppresses Oncogenic Wnt/ß-Catenin Signaling.
Hwang SY, Deng X, Byun S, Lee C, Lee SJ, Suh H, Zhang J, Kang Q, Zhang T, Westover KD, Mandinova A, Lee SW Cell reports 2016 Jun 16 1 28-36
Precision Hypofractionated Radiation Therapy in Poor Performing Patients With Non-Small Cell Lung Cancer: Phase 1 Dose Escalation Trial.
Westover KD, Loo BW, Gerber DE, Iyengar P, Choy H, Diehn M, Hughes R, Schiller J, Dowell J, Wardak Z, Sher D, Christie A, Xie XJ, Corona I, Sharma A, Wadsworth ME, Timmerman R International journal of radiation oncology, biology, physics 2015 Sep 93 1 72-81
In situ selectivity profiling and crystal structure of SML-8-73-1, an active site inhibitor of oncogenic K-Ras G12C.
Hunter JC, Gurbani D, Ficarro SB, Carrasco MA, Lim SM, Choi HG, Xie T, Marto JA, Chen Z, Gray NS, Westover KD Proceedings of the National Academy of Sciences of the United States of America 2014 Jun 111 24 8895-900
Discovery of Type II Inhibitors of TGFß-Activated Kinase 1 (TAK1) and Mitogen-Activated Protein Kinase Kinase Kinase Kinase 2 (MAP4K2).
Tan L, Nomanbhoy T, Gurbani D, Patricelli M, Hunter J, Geng J, Herhaus L, Zhang J, Pauls E, Ham Y, Choi HG, Xie T, Deng X, Buhrlage SJ, Sim T, Cohen P, Sapkota G, Westover KD, Gray NS Journal of medicinal chemistry 2014 Jul
Quantitative analysis of HSP90-client interactions reveals principles of substrate recognition.
Taipale M, Krykbaeva I, Koeva M, Kayatekin C, Westover KD, Karras GI, Lindquist S Cell 2012 Aug 150 5 987-1001
Comprehensive and efficient HBB mutation analysis for detection of beta-hemoglobinopathies in a pan-ethnic population.
Chan OT, Westover KD, Dietz L, Zehnder JL, Schrijver I American journal of clinical pathology 2010 May 133 5 700-7
Structural basis of transcription: an RNA polymerase II-TFIIB cocrystal at 4.5 Angstroms.
Bushnell DA, Westover KD, Davis RE, Kornberg RD Science (New York, N.Y.) 2004 Feb 303 5660 983-8
Restoration of mutant K-Ras repressed miR-199b inhibits K-Ras mutant non-small cell lung cancer progression.
Jin H, Jang Y, Cheng N, Li Q, Cui PF, Zhou ZW, Jiang HL, Cho MH, Westover KD, Tan QY, Xu CX, Journal of experimental & clinical cancer research : CR 2019 Apr 38 1 165
Tissue-specific oncogenic activity of K-RasA146T.
Poulin EJ, Bera AK, Lu J, Lin YJ, Strasser SD, Paulo JA, Huang TQ, Morales C, Yan W, Cook J, Nowak JA, Brubaker DK, Joughin BA, Johnson CW, DeStefanis RA, Ghazi PC, Gondi S, Wales TE, Iacob RE, Bogdanova L, Gierut JJ, Li Y, Engen JR, Perez-Mancera PA, Braun BS, Gygi SP, Lauffenburger DA, Westover KD, Haigis KM, Cancer discovery 2019 Apr
Development of a Selective CDK7 Covalent Inhibitor Reveals Predominant Cell-Cycle Phenotype.
Olson CM, Liang Y, Leggett A, Park WD, Li L, Mills CE, Elsarrag SZ, Ficarro SB, Zhang T, Düster R, Geyer M, Sim T, Marto JA, Sorger PK, Westover KD, Lin CY, Kwiatkowski N, Gray NS Cell chemical biology 2019 Mar
Leveraging Compound Promiscuity to Identify Targetable Cysteines within the Kinome.
Rao S, Gurbani D, Du G, Everley RA, Browne CM, Chaikuad A, Li T, Schröder M, Gondi S, Ficarro SB, Sim T, Kim ND, Berberich MJ, Knapp S, Marto JA, Westover KD, Sorger PK, Gray NS, Cell chemical biology 2019 Mar
Coordinating Tissue Regeneration Through Transforming Growth Factor-ß Activated Kinase 1 Inactivation and Reactivation.
Hsieh HHS, Agarwal S, Cholok DJ, Loder SJ, Kaneko K, Huber A, Chung MT, Ranganathan K, Habbouche J, Li J, Butts J, Reimer J, Kaura A, Drake J, Breuler C, Priest CR, Nguyen J, Brownley C, Peterson J, Ozgurel SU, Niknafs YS, Li S, Inagaki M, Scott G, Krebsbach PH, Longaker MT, Westover K, Gray N, Ninomiya-Tsuji J, Mishina Y, Levi B, Stem cells (Dayton, Ohio) 2019 Feb
- Safety Analysis From a Prospective Registry Study of Stereotactic Body Radiation Therapy for Aggressive Management of Late-Stage Disease.
- Use of technology to improve cancer care
- Structural biology
- Stereotactic radiation therapy
- RAS biology and inhibitor development
- Kinase biology and inhibitor development
- Cancer therapeutics
- Cancer imaging
- Radiation Therapy for Esophageal Cancer
- Chest Cancers
- Brain Metastases
- Pulmonary/Lung-Chest Wall-Mediastinal-Pleural Nodules
- Radiation Therapy for Lung Cancer